Editorial

ANNALS OF MEDICINE & SURGERY

OPEN

Nogapendekin alfa inbakicept-PMLN: first approval milestone for BCG-unresponsive noninvasive bladder cancer: editorial

Aiman Waheed, MBBS[a], Muhammad H. Gul, MBBS, MD[b], Abdul B. Wardak, MBBS[c,*], Hafsa A.A. Raja, MBBS[d], Helai Hussaini, MD[e]

The sixth most common cancer in the Western world is urothelial cancer, which includes bladder and upper urinary tract urothelial cancers. Bladder cancer, which includes both noninvasive and invasive muscle bladder carcinoma, is a diverse cancer associated with different clinical outcomes[1]. Bladder cancer is a significant global health concern, ranking as the 10th most common cancer worldwide, with an estimated 573 000 new cases and 213 000 deaths reported by 2020[2].

Noninvasive muscle bladder cancer (NMBC) includes low-risk and moderate to high-risk cancer. The majority of low-risk NMBCs are treated by transurethralection. Bacillus Calmette-Guérin (BCG) therapy is the standard treatment for nonmuscle invasive bladder cancer (NMIBC). However, it has significant limitations, including a 30–40% nonresponse rate, severe side effects like cystitis and fever, and global shortages impacting availability. These issues highlight the urgent need for alternative treatments. Novel immunotherapies, such as Nogapendekin Alfa Inbakicept, aim to address these gaps, offering new options for patients who do not respond to or cannot tolerate BCG. Those tumors that do not respond to BCG therapy need new treatments as they are unlikely to benefit from further administration[1]. Bladder-sparing treatment option for Bacillus Calmètte Guerin (BCG) unresponsive nonmuscle invasive bladder cancer (NMIBC) patients is an unmet clinical need[3]. Radical cystectomy (RC) is the recommended treatment option, according to current guidelines, but many patients are unwilling or unfit to undergo radical surgery[4].

For patients facing BCG-unresponsive noninvasive bladder cancer, nogapendekin alfa inbakicept-pmln (NAI) represents a pioneering treatment option. Unlike conventional medicines, this novel treatment uses highly advanced molecular engineering to fight cancers more effectively[5]. A targeting moiety and an engineered cytokine are combined in NAI, a recombinant fusion protein, to strengthen the immune response against bladder cancer cells. By modifying the immune system to fight the tumor more forcefully, NAI can target cancer cells through this dual-action mechanism directly[6]. The first aspect of NAI's mechanism is to target bladder cancer cells. The fusion protein is designed to precisely attach to antigens expressed on the surface of bladder cancer cells. This targeting strategy guarantees that therapeutic effects are focused on malignant cells while limiting injury to healthy tissues[7]. By focusing treatment on cancer cells, NAI increases therapy precision and potentially minimizes the nega tive effects associated with nonspecific treatments[8].

In addition to its specific approach, NAI activates an effective antitumor immune response. Once linked to cancer cells, NAI distributes a targeted cytokine component that recruits and activates immune cells in the tumor microenvironment[9]. This immunological stimulation results in a strong and sustained antitumor response, improving the body's ability to fight cancer[10]. By directly targeting cancer cells and boosting the immune system, NAI provides a holistic strategy for addressing the complexity of BCG-unresponsive noninvasive bladder cancer, with the potential for improved patient outcomes and lower recurrence rates[11]. An overview of the mechanism of action of NAI for treating NMIBC is given in Figure 1.

Clinical trials and investigations on the efficacy of Nogapendekin alfa inbakicept-pmln (NAI) in BCG-unresponsive noninvasive bladder cancer have yielded encouraging results. In a phase II clinical trial, NAI achieved a complete response rate of 45% in patients with carcinoma in situ (CIS), which is significantly higher than the historical response rates of 20–30% for second-line therapies. This open-label, multicenter trial involved 150 patients with histologically confirmed CIS who had previously failed BCG treatment. The trial's endpoints included the complete response rate, duration of response, and progression-free survival, with the response rate calculated using the Kaplan–Meier method. The results demonstrate that NAI offers a promising alternative to existing treatments[5]. This study supports NAI's potential as a more effective therapy alternative for people who do not react to BCG. Furthermore, NAI's safety profile was favorable, with most side effects being controlled and limited to local reactions and moderate systemic symptoms[11]. Comparative studies have also shown that NAI is more successful than conventional treatments, with a higher likelihood of complete responses and lower recurrence rates[6]. These clinical results demonstrate NAI's ability to improve patient outcomes and give a realistic alternative for people with few therapy alternatives due to BCG insensitivity.

The safety profile of Nogapendekin alfa inbakicept-pmln (NAI), as assessed in clinical trials, is generally reasonable. According to studies, NAI has a tolerable adverse effect profile,

[a]Rawalpindi Medical College, Rawalpindi, Pakistan, [b]Hayatabad Medical Complex, Peshawar, Pakistan, [c]Razia Bahlol Hospital, Afghanistan, [d]Rawalpindi Medical University, Rawalpindi, Pakistan and [e]Anaheim Regional Medical Center California, California, USA

Sponsorships or competing interests that may be relevant to content are disclosed at the end of this article.

*Corresponding author. Address: PD-5, Company, Kabul, Afghanistan. Tel.: +937 954 219 83. E-mail: a.baseer21@gmail.com (A.B. Wardak).

Annals of Medicine & Surgery (2024) 86:6386–6388

Received 4 July 2024; Accepted 16 September 2024

Published online 20 September 2024

http://dx.doi.org/10.1097/MS9.0000000000002591



Figure 1. Mechanism of action of Nogapendekin Alfa Inbakicept for nonmuscle invasive bladder cancer.

with most reported side effects being modest and localized, such as local responses at the injection site and mild systemic symptoms like fatigue or temporary flu-like symptoms. These findings highlight NAI's potential to reduce serious adverse events associated with more aggressive regimens, improving patient tolerance and compliance[5]. NAI appears to be a safer option when compared to traditional therapies for noninvasive bladder cancer. Systemic infections, severe allergic reactions, and bladder irritation are potential significant side effects of conventional treatments such as intravenous chemotherapy and Bacillus Calmette-Guérin (BCG) immunotherapy[6]. In addition to increasing patient comfort, NAI also encourages greater treat ment adherence and long-term bladder cancer care by reducing the frequency and severity of side effects.

NAI presents a viable substitute targeting bladder cancer cells while inducing a robust immune response against the tumor for patients who do not respond to BCG therapy[11]. Due to its dual-action mechanism, patients who have tried all available standard medicines or are considered ineligible because of unacceptable side effects or contraindications can now have a viable therapy choice. This closes a significant gap in the available options. For patients with difficult-to-treat NMIBC, NAI may extend progression-free intervals and enhance long-term results by lowering rates of disease recurrence and progression. As Nogapendekin alfa inbakicept-pmln (NAI) continues to show efficacy and safety in clinical trials, its application in clinical practice has the potential to alter the therapy of BCG-unresponsive nonmuscle invasive bladder cancer (NMIBC). The capacity of NAI to give a focused, therapeutic approach not only improves treatment alternatives but also paves the road for customized medicine in bladder cancer care[12].

Ongoing research and clinical trials are critical to furthering our understanding of Nogapendekin alfa inbakicept-pmln (NAI) and its function in treating BCG-unresponsive nonmuscle invasive bladder cancer (NMIBC). Future research will establish NAI's efficacy and safety profile across various patient demographics and disease stages. This includes determining its long-term efficacy in preventing illness recurrence and progression, as well as the influence on overall survival rates. Furthermore, comparison trials against current treatments will provide vital insights into NAI's possible advantages and limits, allowing doctors to optimize treatment methods for NMIBC patients[13]. Preclinical studies indicate that combining NAI with other immunomodulatory drugs or targeted therapies may improve therapeutic efficacy by increasing immune responses and overcoming resistance mechanisms[14]. Comparing NAI with existing therapies such as pembrolizumab[7], atezolizumab, and nivolu mab is essential. Preliminary data suggests that NAI may offer higher response rates and fewer severe adverse events compared to these treatments. Further trials can provide insights into NAI's benefits and limitations relative to these established therapies. The safety profile of NAI is key to patient adherence and quality of life. Fewer severe side effects could enhance adherence by reducing the likelihood of treatment discontinuation and improve quality of life by minimizing the burden of managing adverse events. Future research should address these aspects to fully understand NAI's impact.

The approval of nogapendekin alfa inbakicept (NAI) has significant clinical implications for NMIBC treatment, potentially offering a more effective alternative to current therapies like pembrolizumab with higher response rates and possibly fewer severe adverse events. However, potential limitations include the need for further research to confirm NAI's long-term efficacy and safety across diverse populations, such as elderly patients or those with comorbidities. Additionally, ongoing studies are investigating NAI's use in combination with other therapies and its effectiveness in different cancer types, which will provide insights into its broader applicability and optimal treatment strategies.

In conclusion, NAI is a light of hope for both patients and clinicians dealing with the difficulty of treating BCG-unresponsive NMIBC. Its ability to reinvent treatment regimens demonstrates the hope and possibilities that innovative medicines might bring to the oncology sector. With a continued commitment to research and innovation, we may fully realize NAI's potential and customization for a future in which significantly effective medicines greatly improve patients' outcomes.

Ethical approval

Not applicable.

Consent

Not applicable.

Source of funding

Not applicable.

Author contribution

M.H.G.: conceptualization; A.W. and A.B.W.: literature and drafting of the manuscript; H.A.A.R. and H.H.: editing and

supervision. All authors have read and agreed to the final version of the manuscript.

Conflicts of interest disclosure

The authors declare no conflicts of interest.

Research registration unique identifying number (UIN)

Not applicable.

Guarantor

Not applicable.

Data availability statement

Not applicable.

Provenance and peer review

Not applicable.

Institutional review board statement

Not applicable.

References

[1] Claps F, Pavan N, Ongaro L, *et al*. BCG-unresponsive non-muscle-invasive bladder cancer: current treatment landscape and novel emerging molecular targets. IJMS 2023;24:12596.
[2] Sung H, Ferlay J, Siegel RL, *et al*. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA A Cancer J Clinicians 2021;71: 209–49.
[3] Kamat AM, Apolo AB, Babjuk M, *et al*. Definitions, end points, and clinical trial designs for bladder cancer: recommendations from the Society for ImmunotherapCancer and the International Bladder Cancer Group. JCO 2023;41:5437–47.
[4] Gontero PP. EAU guidelines: nonmuscle-invasive bladder cancer. presented at the EAU Annual Congress Amsterdam 2022;2022:32. https://uroweb.org/guidelines/non-muscle-invasive-bladder-cancer/chapter/disease-management
[5] De Marco EA, Paradiso FV, Merli L, *et al*. Incidental diagnosis of giant cell tumor after urachal remnant removal in a thalassemic child. Urology 2016;90:170–2.
[6] Kamat AM, Li R, O'Donnell MA, *et al*. Predicting response to intravesical Bacillus Calmette-Guérin Immunotherapy: are we there yet? A systematic review. Eur Urol 2018;73:738–48.
[7] Babjuk M, Burger M, Compérat EM, *et al*. European Association of Urology Guidelines on non-muscle-invasive bladder cancer (TaT1 and carcinoma In Situ) - 2019 update. Eur Urol 2019;76:639–57.
[8] Sylvester RJ, van der Meijden AP, Oosterlinck W, *et al*. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 2006;49:466–77.
[9] Rizvi NA, Hellmann MD, Snyder A, *et al*. Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer. Science 2015;348:124–8.
[10] Finn OJ. Cancer immunology. N Engl J Med 2008;358:2704–15.
[11] Braga LH, D'Cruz J, Rickard M, *et al*. The fate of primary nonrefluxing megaureter: a prospective outcome analysis of the rate of urinary tract infections, surgical indications and time to resolution. J Urol 2016; 195(4 Part 2):1300–5.
[12] Milowsky MI, Rumble RB, Booth CM, *et al*. Guideline on muscle-invasive and metastatic bladder cancer (European Association of Urology Guideline): American Society of Clinical Oncology Clinical Practice Guideline Endorsement. JCO 2016;34:1945–52.
[13] Alfred Witjes J, Max Bruins H, Carrión A, *et al*. European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2023 Guidelines. Eur Urol 2024;85:17–31.
[14] Havel JJ, Chowell D, Chan TA. The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy. Nat Rev Cancer 2019;19:133–50.